top of page

SwissMedic Guidance on Fast-Track Authorisation, Temporary Authorisation and Variations & Extensions

Writer's picture: Sharan MuruganSharan Murugan

Last week Swissmedic, the Swiss Agency for Therapeutic Products updated and released 3 Important guidances and forms.

This guidance document explains the requirements pertaining to variations and extensions for human medicinal products.


Download the most recent form for Variations and extensions by clicking this LINK.


Temporary authorizations are granted under exceptional circumstances when there is an urgent medical need, such as during public health emergencies or when no alternative treatments are available.


This guidance describes the conditions that must be met before a request for temp.auth or temp.AI can be approved, as well as the detailed procedures for the meeting with applicants (AAA) during which the request will be processed and evaluated.


This guide provides information about how to apply for a fast-track procedure (FTP) and explains the requirements that must be met for an FTP application to be approved and outlines the detailed procedure for a meeting with the applicant called the Accelerated Application Hearing (AAA), which is scheduled to process the application.


Click this LINK to download the recent "Decision Minutes Accelerated Application Hearing" application.



コメント


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page